Dr Tarik Regad is a Senior Research Fellow in Molecular and Cellular Tumour Biology and his research focuses on investigating the role of cancer stem cells in cancer initiation, invasion and metastasis. He is also involved in delivering lectures and practical sessions on cancer and cancer stem cells for post-graduate level students within the module Biology of Disease.
Dr Regad is a Doctor of Veterinary Medicine (DvetMed). He undertook his MSc, MRes and PhD at the University Paris VII (Denis Diderot) before joining the Gurdon Institute at the University of Cambridge (UK) as a Research Associate. In 2006, he moved to the MRC Toxicology Unit (University of Leicester) to undertake a position as a Career Development Fellow. He joined NTU in 2010 as a Lecturer/Senior Lecturer in Biosciences and he is now working as a Senior Research Fellow at the John van Geest Cancer Research Centre.
Cancer stem cells (CSCs) are responsible for cancer initiation, invasion and metastasis in patients who were subjected to cancer therapies such as chemotherapy or radiotherapy. Therefore, the major challenges facing the cancer scientific community reside in identifying those malignant cells and develop therapies to target them. His projects are carried out at the John van Geest Cancer Research Centre and focus on:
- Identifying tissue specific CSCs
- Identifying CSCs specific biomarkers
- Developing CSCs targeting strategies (Antibody therapy, Nanotechnology-based Trageting, Chemical therapy, Immunotherapy)
- Investigating the molecular and cellular processes involved in cancer invasion and metastasis.
Opportunities arise to carry out postgraduate research towards an MPhil / PhD in the areas identified above. Further information may be obtained on the NTU Research Degrees website https://www.ntu.ac.uk/research/research-degrees-at-ntu.
A programme of fully-funded PhD studentships for UK, EU or international students at NTU is now open for application until the 25th February 2019.
- Member of the British Society for Cell Biology (BSCB).
- Member of the European Association for Cancer Research (EACR).
- Fellow of the Higher Education Academy (HEA).
- Editorial Board Member/Translational Medicine Reports.
- Member of Organising committee of the 2nd International Symposium on The Future of Regenerative Medicine, Ostuni, Italy (3-5 Oct 2018).
- Principal Investigator and Member of IMMUTRAIN/Training Network for the Immunotherapy of Cancer
- Visiting Professor (2016)/Università degli Studi della Campania "Luigi Vanvitelli, Naples (Italy).
MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer. Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T. Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.
A promyelocytic leukemia protein-thrombospondin 2 axis and the risk of relapse in neuroblastoma. Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Le Bras M, Burns A, Saunders N, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A and Salomoni P, Clinical Cancer Research, 2016, 22 (15)
Cytoplasmic PML promotes TGF-β-associated epithelial–mesenchymal transition and invasion in prostate cancer. Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, Van Schalkwyk G, Parkinson R, Hulman J, Powe DG and Regad T, Oncogene, 2015
Targeting RTK signaling pathways in cancer., Cancers. Regad, T, Cancers, 2015, 7 (3), 1758-1784
The helicase HAGE prevents interferon-a-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1. Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC and Regad T, Cell Death and Disease, 2014, 5 (2)
The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SEB, Regad T, Journal of Biological Chemistry, 2012, 287 (17), 13633-13643
The tumour suppressor Pml regulates cell fate in the developing neocortex. Regad T, Bellodi C, Nicotera P and Salomoni P, Nature Neuroscience, 2009, 2 (2), 132-40See all of Tarik Regad's publications...
- Stem cells
- Cancer stem cells
- Cancer therapies (chemical and monoclonal antibody targeting)
- Cancer initiation and progression (invasion and metastasis)